ERNA: Eterna Therapeutics Inc. Stock

by  •  • Comments Off on ERNA: Eterna Therapeutics Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 10.93
Enterprise Value ($M) 10.13
Book Value ($M) 2.23
Book Value / Share 0.41
Price / Book 4.89
NCAV ($M) -37.30
NCAV / Share -6.89
Price / NCAV -0.29

Profitability (mra)
Return on Invested Capital (ROIC) -0.49
Return on Assets (ROA) -1.43
Return on Equity (ROE) -2.94

Liquidity (mrq)
Quick Ratio 1.46
Current Ratio 1.46

Balance Sheet (mrq) ($M)
Current Assets 9.60
Assets 49.13
Liabilities 46.90
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.07
Operating Income -20.68
Net Income -21.67
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -20.41
Cash from Investing -0.02
Cash from Financing 16.56

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-19 13G/A Singer Nicholas Jason 9.99 7.73
12-22 13D/A Cherington Charles 19.99 0.00
12-20 13G Iaf, Llc 9.99
08-28 13G Purchase Capital LLC 5.00
07-21 13G/A Freebird Partners LP 19.99 51.04

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-18 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1)
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION R
2023-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-10 1,370 821 166.87
2024-05-09 561 498 112.65
2024-05-08 19,338 2,782 695.11
2024-05-07 1,999 1,655 120.79

(click for more detail)

Similar Companies
ENVB – Enveric Biosciences, Inc. EPIX – ESSA Pharma Inc.
EQ – Equillium, Inc. ESLA – Estrella Immunopharma, Inc.
EVOK – Evoke Pharma, Inc.


Financial data and stock pages provided by
Fintel.io